Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $10.2 million.

  • OptimizeRx's Accumulated Expenses rose 8351.63% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 8351.63%. This contributed to the annual value of $8.5 million for FY2024, which is 1012.2% up from last year.
  • Latest data reveals that OptimizeRx reported Accumulated Expenses of $10.2 million as of Q3 2025, which was up 8351.63% from $12.5 million recorded in Q2 2025.
  • OptimizeRx's Accumulated Expenses' 5-year high stood at $12.5 million during Q2 2025, with a 5-year trough of $869791.0 in Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $2.9 million (2021), whereas its average is $4.7 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 4805.6% in 2021, then soared by 25318.13% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Accumulated Expenses stood at $2.9 million in 2021, then decreased by 10.39% to $2.6 million in 2022, then soared by 196.24% to $7.7 million in 2023, then grew by 10.12% to $8.5 million in 2024, then grew by 20.17% to $10.2 million in 2025.
  • Its Accumulated Expenses was $10.2 million in Q3 2025, compared to $12.5 million in Q2 2025 and $9.3 million in Q1 2025.